STOCK TITAN
  1. Home
  2. News
  3. CELZ

Creative Medical Technology Holdings Inc - CELZ STOCK NEWS

Welcome to our dedicated news page for Creative Medical Technology Holdings (Ticker: CELZ), a resource for investors and traders seeking the latest updates and insights on Creative Medical Technology Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Creative Medical Technology Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Creative Medical Technology Holdings's position in the market.

News
Creative Medical Technology Holdings Provides Corporate Update
Rhea-AI Summary
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) provides a corporate update highlighting FDA approvals for regenerative medicine therapies to treat Type 1 Diabetes and chronic lower back pain. The company's financial position remains strong with cash and investments of $10 million and a share repurchase program in place.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
none
-
News
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
Rhea-AI Summary
Creative Medical Technology Holdings, Inc. (CELZ) achieves FDA approval for CELZ-201, a groundbreaking therapy to prevent Type 1 Diabetes Mellitus. The personalized medicine approach targets high-risk individuals, showcasing the company's commitment to innovative healthcare solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.35%
Tags
none
-
News
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
Rhea-AI Summary
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) receives Orphan Drug Designation from the FDA for CELZ-101, ImmCelzTM, a cutting-edge therapy aimed at preventing allograft rejection in pancreatic islet cell transplantation for brittle Type 1 diabetes. The therapy utilizes the patient's own regulatory T cells to combat autoimmune responses, offering a promising solution to reduce lifelong immunosuppression. This designation provides tax advantages, user fee exemptions, and market exclusivity post-approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.28%
Tags
clinical trial
News
Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain
Rhea-AI Summary
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Receives FDA Clearance for Phase 1/2 Clinical Trial for AlloStem™ Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Creative Medical Technology Holdings Provides Corporate Update
Rhea-AI Summary
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) provided an update on its regenerative therapies for diabetes and chronic lower back pain, emphasizing its strong financial position with no long-term debt. The company is using its proprietary AlloStem™ cell line for separate clinical trials for Type 1 Diabetes (CELZ-201) and the treatment of chronic lower back pain with its StemSpine® procedure (CELZ-201-DDT). It also highlighted its substantial intellectual property portfolio and partnerships with respected institutions and companies. The company received FDA clearance for a Phase I/II clinical trial of StemSpine® for lower back pain and has an FDA-cleared and IRB-approved Phase I/II clinical trial for the use of AlloStem™ for patients suffering from early Type 1 Diabetes. Additionally, it presented positive one-year follow-up data for patients with Type 2 Diabetes using CELZ-001. The company is also making progress in advancing its ImmCelz® platform, with plans to explore licensing and supplying cells to other companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.3%
Tags
none
-
News
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain
Rhea-AI Summary
Creative Medical Technology receives IRB approval for clinical trial on CELZ-201-DDT for chronic lower back pain
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
clinical trial
News
Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain
Rhea-AI Summary
Creative Medical Technology Holdings, Inc. receives FDA clearance for Phase 1/2 clinical trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for chronic lower back pain. CELZ-201-DDT has potential as a non-surgical pain management option compared to opioids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
clinical trial
-
News
What Is Allogeneic Cell Therapy, And What’s Driving This Market’s 25%+ Annual Global Growth?
Rhea-AI Summary
Biotech company Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) announces success in allogeneic cell therapy market with development of AlloStem™. CELZ-201 now in early type 1 diabetes clinical trial. AlloStem™ also shows promise in treating chronic back pain. Global allogeneic cell therapy market expected to grow at CAGR of 27.4% from 2023 to 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
none
-
News
Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update
Rhea-AI Summary
Creative Medical Technology Holdings, Inc. provides an update on its drug pipeline and financial standing. The company has no long-term debt and has $14.6 million in cash and certificates of deposit. They project enough money to meet operating costs and capital expenditures through 2024. The company has achieved significant milestones in developing treatments for type 1 diabetes and type 2 diabetes. They also announced positive results from a pilot study on chronic lower back pain. Creative Medical Technology is focused on regenerative medicine and improving patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.84%
Tags
none
News
Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
none
Stock CELZ logo
Creative Medical Technology Holdings Inc

Nasdaq:CELZ

CELZ Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

CELZ Stock Data

7.07M
1.32M
2.71%
1.45%
2.12%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Phoenix

About CELZ

creative medical technology holdings, inc., through its subsidiaries, engages in the stem cell research and developing applications to treat male sexual dysfunction and related issues. the company markets its erectile dysfunction (ed) treatment under the caverstem name to physicians for use with their patients suffering from ed. creative medical technology holdings, inc. was incorporated in 1998 and is based in phoenix, arizona. creative medical technology holdings, inc. is a subsidiary of creative medical health, inc.